BRINSUPRI

FDA approvals

FDA Approval of Brensocatib Signals New Era for NCFB Treatment: Strategic Implications for China’s Respiratory Pipeline

Insmed’s FDA approval of BRINSUPRI™ (brensocatib) for non-cystic fibrosis bronchiectasis marks a new era for neutrophil-targeted therapies. Originally discovered by AstraZeneca, brensocatib's success could reshape China’s respiratory drug innovation and investment landscape.